United Therapeutics Corp (UTHR) CEO trades options and common shares
Rhea-AI Filing Summary
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share on July 16, 2026, and on the same date sold 9,500 shares of common stock in multiple trades, including a tranche at a weighted average price of $530.1449 per share. These option exercises and sales were carried out by a family trust under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. After these transactions, that family trust held 324,443 shares of United Therapeutics common stock, while Rothblatt also reported 40,513 shares held directly and 331,910 stock options held in a family trust.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.76M approx. pre-tax spread)
Exercise and Sale
16 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.04M)
Approx. gross sale proceeds
$5.04M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.76M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F15 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 80 | $527.3135 | $42K |
| Sale | Common Stock F1, F4, F2 | 1,400 | $528.4164 | $740K |
| Sale | Common Stock F1, F5, F2 | 3,057 | $529.4641 | $1.62M |
| Sale | Common Stock F1, F6, F2 | 1,924 | $530.1449 | $1.02M |
| Sale | Common Stock F1, F7, F2 | 520 | $532.1375 | $277K |
| Sale | Common Stock F1, F8, F2 | 440 | $533.2827 | $235K |
| Sale | Common Stock F1, F9, F2 | 1,198 | $534.3077 | $640K |
| Sale | Common Stock F1, F10, F2 | 720 | $535.1978 | $385K |
| Sale | Common Stock F1, F11, F2 | 150 | $536.2871 | $80K |
| Sale | Common Stock F1, F2 | 11 | $537.11 | $6K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F12 | -- | -- | -- |
| holding | Common Stock F13 | -- | -- | -- |
| holding | Common Stock F14 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 331,910 shares (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct)
Footnotes (15)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $526.88 to $527.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $527.88 to $528.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $528.88 to $529.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $529.88 to $530.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $531.50 to $532.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $532.58 to $533.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $533.77 to $534.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F10. This transaction was executed in multiple trades at prices ranging from $534.79 to $535.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $535.98 to $536.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F13. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F14. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F15. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
Key Figures
Shares sold: 9,500 shares
Options exercised: 9,500 shares at $135.4200
Example sale price: $530.1449 per share
+4 more
7 metrics
Shares sold
9,500 shares
Total United Therapeutics common shares sold on 2026-07-16
Options exercised
9,500 shares at $135.4200
Stock options exercised into common stock on 2026-07-16
Example sale price
$530.1449 per share
Weighted average sale price for one tranche of UTHR shares on 2026-07-16
Trust share holdings
324,443 shares
Common shares held by the trading family trust after 2026-07-16 transactions
Direct share holdings
40,513 shares
Common shares held directly by the reporting person as of 2026-07-16
Stock options held
331,910 options
Stock options held in a family trust after the reported option exercise
Plan option capacity
1,734,410 stock options
Maximum options covered by the Rule 10b5-1 plan, expiring March 15, 2027
Key Terms
Rule 10b5-1 trading plan, weighted average price, family trusts, stock options
4 terms
Rule 10b5-1 trading plan financial
"exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
stock options financial
"This exercise of stock options and sale of the resulting shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Martine A. Rothblatt report for UTHR on July 16, 2026?
Martine A. Rothblatt reported exercising 9,500 stock options at $135.42 per share and selling 9,500 United Therapeutics common shares in multiple trades, including a tranche at a weighted average price of $530.1449 per share, all on July 16, 2026.
Were Martine A. Rothblatt’s UTHR trades made under a Rule 10b5-1 plan?
Yes. The option exercise and related share sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan continues until the earlier of exercising 1,734,410 stock options or December 31, 2026.
What is the strike price and term of Rothblatt’s United Therapeutics stock options?
The reported option exercise involved 9,500 stock options with an exercise price of $135.42 per share. Footnotes state the plan covers up to 1,734,410 options, all expiring on March 15, 2027, with the trading plan ending no later than December 31, 2026.